Evidence map›Paper›PMID 38352152›Full record

ArticleOpen forum infectious diseases2024

Association of Nirmatrelvir/Ritonavir Treatment and COVID-19-Neutralizing Antibody Titers in a Longitudinal Health Care Worker Cohort.

Slade Decker, Shaoming Xiao, Carly Dillen, Christina M Schumacher, Aaron M Milstone, Matthew Frieman, Amanda K Debes

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Slade DeckerJohns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Shaoming XiaoJohns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Carly DillenCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Christina M SchumacherJohns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Aaron M MilstoneJohns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Matthew FriemanCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Amanda K DebesJohns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-4006-073X
Johns Hopkins University · USUniversity of Maryland, Baltimore · US

Funding

Mentoring in prevention of hospital-acquired infections and antibiotic resistanceK24AI141580 · NIAID · JOHNS HOPKINS UNIVERSITY · PI AARON M MILSTONE · 2019 to 2026
$1.4M
NIAID NIH HHS K24 AI141580
6 · The paper itself

Abstract

Nirmatrelvir/ritonavir (NMV/r) is used for the treatment of coronavirus disease 2019 (COVID-19) infection. However, rebound COVID-19 infections can occur after taking NMV/r. We examined neutralizing antibodies to the severe acute respiratory syndrome coronavirus 2 spike protein before and after infection in people who did and did not take NMV/r to determine if NMV/r impedes the humoral immune response.

Indexed as

antibodiesantiviralsCOVID-19humoral immune responseimmunologylongitudinal cohortNMV/r

Identifiers

PMID38352152
PMCPMC10863641
OpenAlexW4391775932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.